Technology
AstraZeneca, AI biologics firm Absci tie up on cancer drug
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with US artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci said in a statement on Sunday.
Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. It did not say what kind of cancer they plan to target.
Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.
"We're proud to work closely with AstraZeneca to leverage our AI to bring novel treatments to oncology patients," Absci CEO Sean McClain said.
AstraZeneca did not immediately respond to a Reuters requests for comment.
The Financial Times, which first reported the deal, said it includes an upfront fee for Absci, research and development funding and milestone payments, and royalties on any product sales.
-
Technology14h ago
Inside the New Nonprofit AI Initiatives Seeking to Aid Teachers and Farmers in Rural Africa
-
Technology15h ago
Is AI dominance inevitable? A technology ethicist says no, actually
-
Technology22h ago
Chinese roverfinds signs of ancient ocean on Mars | The Express Tribune
-
Technology1d ago
Karachi university students create world's smallest nebuliser | The Express Tribune
-
Technology1d ago
Colorado company is building its own WALL-E as it reimagines trash disposal, recycling in outer space
-
Technology1d ago
Black hole after 1.5b years of Big Bang | The Express Tribune
-
Technology2d ago
How We Picked the Best Inventions of 2024
-
Technology2d ago
Turning Simple Dresses into Statement Looks with Accessories